ArticleBMC urology2013

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain.

Antoni Sicras-Mainar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.